Jupiter Asset Management Boosts Stake in Royalty Pharma with $4.95M Investment Jupiter Asset Management has acquired $4.95 million in shares of Royalty Pharma plc, signaling confidence in the biopharmaceutical royalty company. Royalty Pharma recently reported strong financials, including a 24.4% return on equity, and increased its dividend payout. Analysts have largely rated the company as a "buy," with a positive outlook for growth.34